NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

Novo Nordisk faces a class-action lawsuit over misleading claims about its obesity drug, CagriSema. Following disappointing trial results, the stock dropped $18.44 to $85.00 per share.

Novo Nordisk has acquired global rights to obesity and diabetes drug UBT251 for up to $2 billion, including $200 million upfront. The drug is in phase 2 trials in China.

Novo Nordisk cut Wegovy's price to $499 monthly for eligible cash patients in the U.S., down from over $1,000, and expanded its savings program for local pharmacy access.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.